Haemochromatoses. New understanding, new treatments;Les hémochromatoses. Nouvelle compréhension, nouveaux traitements

Gastroenterologie Clinique et Biologique

Volumn 33, Issue 8-9, 2009, Pages 859-867

  Brissot, P ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE MESYLATE; FERROPORTIN; HEMOJUVELIN; HEPCIDIN; SMAD PROTEIN; TRANSFERRIN RECEPTOR 2;

CERULOPLASMIN BLOOD LEVEL; GENE MUTATION; HEMOCHROMATOSIS; HYPERFERRITINEMIA; IRON CHELATION; IRON OVERLOAD; PHLEBOTOMY; SHORT SURVEY;

HEMOCHROMATOSIS; HUMANS;

EID: 70249100219     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.04.004     Document Type: Short Survey

References (52)

1. Trousseau A. Diabète sucré (1865), Baillère, Paris [663-7]
2. Troisier M. Diabète sucré. Bull Soc Anat Paris 44 (1871) 231-235
3. von Recklinghausen F.D. Uber Haemochromatose. Taggeblatt der Versammlungen deutscher Naturforscher und Aerzte in Heidelberg 62 (1889) 324-325
4. Sheldon J. Haemochromatosis (1935), Oxford Univ Press
5. Simon M., Bourel M., Fauchet R., and Genetet B. Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis. Gut 17 (1976) 332-334
6. Feder J.N., Gnirke A., Thomas W., Tsuchihashi Z., Ruddy D.A., Basava A., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13 (1996) 399-408
7. Roetto A., Totaro A., Piperno A., Piga A., Longo F., Garozzo G., et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 97 (2001) 2555-2560
8. Roetto A., Papanikolaou G., Politou M., Alberti F., Girelli D., Christakis J., et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 33 (2003) 21-22
9. Papanikolaou G., Samuels M.E., Ludwig E.H., MacDonald M.L., Franchini P.L., Dube M.P., et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 36 (2004) 77-82
10. Montosi G., Donovan A., Totaro A., Garuti C., Pignatti E., Cassanelli S., et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 108 (2001) 619-623
11. Njajou O.T., Vaessen N., Joosse M., Berghuis B., van Dongen J.W., Breuning M.H., et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 28 (2001) 213-214
12. Pigeon C., Ilyin G., Courselaud B., Leroyer P., Turlin B., Brissot P., et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 276 (2001) 7811-7819
13. Nicolas G., Bennoun M., Devaux I., Beaumont C., Grandchamp B., Kahn A., et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 98 (2001) 8780-8785
14. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 (2004) 2090-2093
15. De Domenico I., Nemeth E., Nelson J.M., Phillips J.D., Ajioka R.S., Kay M.S., et al. The hepcidin-binding site on ferroportin is evolutionarily conserved. Cell Metab 8 (2008) 146-156
16. Brissot P, Le Lan C, Troadec MB, Ropert M, Gaboriau F, Lescoat G, et al. Diagnosis and treatment of HFE-haemochromatosis. In: Handbook ESoH, ed. Disorders of iron homeostasis, Erythrocytes, Erythropoiesis (in press).
17. Brissot P., Troadec M.B., Bardou-Jacquet E., Lan C.L., Jouanolle A.M., Deugnier Y., et al. Current approach to hemochromatosis. Blood Rev 22 (2008) 195-210
18. Pietrangelo A. Hereditary hemochromatosis. A new look at an old disease. N Engl J Med 350 (2004) 2383-2397
19. Beutler E., Felitti V.J., Koziol J.A., Ho N.J., and Gelbart T. Penetrance of 845G: A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 359 (2002) 211-218
20. Allen K.J., Gurrin L.C., Constantine C.C., Osborne N.J., Delatycki M.B., Nicoll A.J., et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 358 (2008) 221-230
21. HAS. French recommendations for management of HFE hemochromatosis. Haute Autorité de santé 2005 : www.has-sante.fr.
22. Camaschella C., Roetto A., Cali A., De Gobbi M., Garozzo G., Carella M., et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 25 (2000) 14-15
23. Miyajima H., Takahashi Y., and Kono S. Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals 16 (2003) 205-213
24. Kono S., Suzuki H., Takahashi K., Takahashi Y., Shirakawa K., Murakawa Y., et al. Hepatic iron overload associated with a decreased serum ceruloplasmin level in a novel clinical type of aceruloplasminemia. Gastroenterology 131 (2006) 240-245
25. Babitt J.L., Huang F.W., Wrighting D.M., Xia Y., Sidis Y., Samad T.A., et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 38 (2006) 531-539
26. Wang R., Li C., Xu X., Zheng Y., Xiao C., Zerfas P., et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2 (2005) 399-409
27. Andrews N.C. Forging a field: the golden age of iron biology. Blood 112 (2008) 219-230
28. Vujic Spasic M., Kiss J., Herrmann T., Galy B., Martinache S., Stolte J., et al. HFE acts in hepatocytes to prevent hemochromatosis. Cell Metab 7 (2008) 173-178
29. De Domenico I., Ward D.M., di Patti M.C., Jeong S.Y., David S., Musci G., et al. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J 26 (2007) 2823-2831
30. Hershko C., Graham G., Bates G.W., and Rachmilewitz E.A. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 40 (1978) 255-263
31. Hider R.C. Nature of nontransferrin-bound iron. Eur J Clin Invest 32 Suppl 1 (2002) 50-54
32. Esposito B.P., Breuer W., Sirankapracha P., Pootrakul P., Hershko C., and Cabantchik Z.I. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102 (2003) 2670-2677
33. Le Lan C., Loreal O., Cohen T., Ropert M., Glickstein H., Laine F., et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 105 (2005) 4527-4531
34. Brissot P., Wright T.L., Ma W.L., and Weisiger R.A. Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J Clin Invest 76 (1985) 1463-1470
35. Gandon Y., Olivié D., Guyader D., Aubé C., Oberti F., Sebille V., et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 33 (2004) 338-343
36. St Pierre T.G., Clark P.R., Chua-anusorn W., Fleming A.J., Jeffrey G.P., Olynyk J.K., et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105 (2005) 855-861
37. Knisely A.S., Gelbart T., and Beutler E. Molecular characterization of a third case of human atransferrinemia. Blood 104 (2004) 2607
38. Mims M.P., Guan Y., Pospisilova D., Priwitzerova M., Indrak K., Ponka P., et al. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood 105 (2005) 1337-1342
39. Beaumont C., Delaunay J., Hetet G., Grandchamp B., de Montalembert M., and Tchernia G. Two new human DMT1 gene mutations in a patient with microcytic anemia, low ferritinemia, and liver iron overload. Blood 107 (2006) 4168-4170
40. Iolascon A., d'Apolito M., Servedio V., Cimmino F., Piga A., and Camaschella C. Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2). Blood 107 (2006) 349-354
41. Camaschella C., Campanella A., De Falco L., Boschetto L., Merlini R., Silvestri L., et al. The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood 110 (2007) 1353-1358
42. Andrews N.C., and Schmidt P.J. Iron homeostasis. Annu Rev Physiol 69 (2007) 69-85
43. Ganz T. Iron homeostasis: fitting the puzzle pieces together. Cell Metab 7 (2008) 288-290
44. Jacolot S., Le Gac G., Scotet V., Quere I., Mura C., and Ferec C. HAMP as a modifier gene that increase the phenotypic expression of the HFE C282Y homozygous genotype. Blood 103 (2004) 2835-2840
45. Merryweather-Clarke A.T., Cadet E., Bomford A., Capron D., Viprakasit V., Miller A., et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 12 (2003) 2241-2247
46. Le Gac G., Scotet V., Ka C., Gourlaouen I., Bryckaert L., Jacolot S., et al. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum Mol Genet 13 (2004) 1913-1918
47. Millet J., Dehais V., Bourgain C., Jouanolle A.M., Mosser A., Perrin M., et al. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway module HFE hemochromatosis penetrance. Am J Hum Genet 81 (2007) 799-807
48. Gurrin L.C., Osborne N.J., Constantine C.C., McLaren C.E., English D.R., Gertig D.M., et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology 135 (2008) 1945-1952
49. Ganz T., Olbina G., Girelli D., Nemeth E., and Westerman M. Immunoassay for human serum hepcidin. Blood 112 (2008) 4292-4297
50. Swinkels D.W., and Drenth J.P. Hepcidin in the management of patients with mild non-hemochromatotic iron overload: fact or fiction?. J Hepatol 49 (2008) 680-685
51. Cappellini M.D., Cohen A., Piga A., Bejaoui M., Perrotta S., Agaoglu L., et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107 (2006) 3455-3462
52. Gattermann N. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk Res 31 Suppl 3 (2007) S10-S15